Hypothesis

Baseline pain tolerance reflects an individual’s capacity for microbiome‑derived short‑chain fatty acid (SCFA) production, which drives hepatic AMPK activation and mitochondrial NAD+ salvage via NAMPT. Consequently, people with higher pain thresholds will show greater increases in NAD+ levels and epigenetic age reversal after acarbose treatment, whereas low pain tolerance predicts blunted metabolic response.

Rationale

• Pain tolerance as a systemic biomarker – Chronic pain perception correlates with inflammatory burden, mitochondrial function, and vagal tone, suggesting it mirrors hidden aging processes [3] [8].
• Acarbose extends lifespan via microbiome‑SCFA‑AMPK axis – Acarbose increases colonic carbohydrate delivery, boosting SCFA‑producing bacteria; portal SCFAs activate hepatic AMPK, which synergizes with mTOR inhibition to prolong life [4] [7] [10].
• NAD+ salvage links AMPK to aging – AMPK activation raises intracellular NAD+ by stimulating NAMPT, enhancing sirtuin activity and mitochondrial health [9].
• Sex‑specific metabolic flexibility influences pain recovery – Females exhibit greater fatty‑acid oxidation capacity that supports pain resilience, while males rely on glycolysis and show worse outcomes [6]; this flexibility may be mirrored in SCFA‑driven AMPK signaling.

Thus, pain tolerance may serve as a readable proxy for the microbiome‑AMPK‑NAD+ circuit that determines how strongly an individual responds to acarbose.

Testable Predictions

1. Cross‑sectional association – In a cohort of 40‑ to 65‑year‑olds, heat pain threshold (HPT) will positively correlate with fecal butyrate proportion, hepatic p‑AMPK levels, and plasma NAD+/NADH ratio, after adjusting for age, sex, BMI, and inflammation (CRP).
2. Intervention response – After 6 months of acarbose (100 mg TID), participants with baseline HPT in the top quartile will exhibit:
   • ≥15 % increase in plasma NAD+,
   • ≥0.05 reduction in GrimAge acceleration,
   • ≥20 % rise in fecal butyrate, whereas the bottom quartile will show <5 % change in these metrics.
3. Mechanistic blockade – A subset receiving broad‑spectrum antibiotics (vancomycin + neomycin) alongside acarbose will lose the pain‑tolerance‑dependent NAD+ and GrimAge benefits, confirming the microbiome’s mediating role.
4. Sex interaction – Females will show a steeper slope between HPT and NAD+ increase than males, reflecting greater metabolic flexibility [6]; however, the overall direction of the association remains consistent across sexes.

Experimental Design

• Participants: 120 middle‑aged adults (60 F, 60 M), stratified by baseline HPT.
• Baseline: Quantitative sensory testing (heat pain 44‑48 °C), fecal SCFA GC‑MS, blood NAD+/NADH, hepatic p‑AMPK (via phospho‑specific ELISA on peripheral mononuclear cells as a proxy), GrimAge from methylation array.
• Intervention: Acarbose 100 mg with each meal for 24 weeks; antibiotic arm receives vancomycin 125 mg q6h + neomycin 500 mg q8h for the first 2 weeks then monthly pulse.
• Endpoints: Repeat all baseline measures at week 12 and week 24.
• Analysis: Mixed‑effects models testing HPT × time interaction on NAD+ and GrimAge, mediation analysis with fecal butyrate as mediator, and subgroup analysis for antibiotic effect.

Potential Outcomes and Implications

If confirmed, pain tolerance would become a rapid, low‑cost predictor of who benefits most from microbiome‑targeted geroprotectors like acarbose, enabling personalized aging interventions. Conversely, a null result would challenge the notion that subjective pain mirrors hidden mitochondrial‑NAD+ dynamics, redirecting focus toward more direct metabolic biomarkers.